Research Institute of Molecular Pathology (IMP)

The Research Institute of Molecular Pathology (IMP) is a leading, basic research institute committed to pushing the frontiers of biomedical science. Since its foundation in 1988, the IMP has created a legacy of research excellence and academic eminence. The IMP is largely sponsored by the pharmaceutical company Boehringer Ingelheim, yet is fully independent in its governance and research programs. The IMP provides its scientists with the resources and freedom they need to follow their own scientific instincts and ideas.

Together with Max F. Perutz Laboratories (MFPL),  the Institute of Molecular Biotechnology (IMBA),  the Gregor Mendel Institute (GMI) of the Austrian Academy of Science and several Biotech companies, the IMP forms the Campus Vienna Biocenter. The IMP shares scientific and administrative services with IMBA and GMI and together with the partners at the campus also operates a publicly-funded scientific support facility, the CSF.

We strongly believe that a supportive and collaborative intellectual culture is essential to attract creative and bold scientists, willing to cross the boundaries of their discipline in pursuite of groundbreaking scientific discoveries.